Diagnostic and Therapeutic Biomarkers in Pancreaticobiliary Malignancy

Overview

Journal World J Gastrointest Endosc

Publisher Baishideng Publishing Group

Date 2016 Feb 11

PMID 26862363

Citations 10

Authors

Domenico Viterbo

Valerie Gausman

Tamas Gonda

Affiliations

Soon will be listed here.

Abstract

Pancreatic ductal adenocarcinoma (PDAC) and cholangiocarcinoma (CCA) are two malignancies that carry significant morbidity and mortality. The poor prognoses of these cancers are strongly related to lack of effective screening modalities as well as few therapeutic options. In this review, we highlight novel biomarkers that have the potential to be used as diagnostic, prognostic and predictive markers. The focus of this review is biomarkers that can be evaluated on endoscopically-obtained biopsies or brush specimens in the pre-operative setting. We also provide an overview of novel serum based markers in the early diagnosis of both PDAC and CCA. In pancreatic cancer, the emphasis is placed on prognostic and theranostic markers, whereas in CCA the utility of molecular markers in diagnosis and prognosis are highlighted.

Citing Articles

Biliary Strictures and Cholangiocarcinoma - Untangling a Diagnostic Conundrum.

Ney A, Garcia-Sampedro A, Goodchild G, Acedo P, Fusai G, Pereira S Front Oncol. 2021; 11:699401.

PMID: 34660269 PMC: 8515053. DOI: 10.3389/fonc.2021.699401.

Practical review for diagnosis and clinical management of perihilar cholangiocarcinoma.

Dondossola D, Ghidini M, Grossi F, Rossi G, Foschi D World J Gastroenterol. 2020; 26(25):3542-3561.

PMID: 32742125 PMC: 7366054. DOI: 10.3748/wjg.v26.i25.3542.

Preoperative CEA levels are supplementary to CA19-9 levels in predicting prognosis in patients with resectable intrahepatic cholangiocarcinoma.

He C, Zhang Y, Song Y, Wang J, Xing K, Lin X J Cancer. 2018; 9(17):3117-3128.

PMID: 30210635 PMC: 6134824. DOI: 10.7150/jca.25339.

Macrophage inhibitory cytokine-1 versus carbohydrate antigen 19-9 as a biomarker for diagnosis of pancreatic cancer: A PRISMA-compliant meta-analysis of diagnostic accuracy studies.

Yang Y, Yan S, Tian H, Bao Y Medicine (Baltimore). 2018; 97(9):e9994.

PMID: 29489701 PMC: 5851718. DOI: 10.1097/MD.0000000000009994.

Modern work-up and extended resection in perihilar cholangiocarcinoma: the AMC experience.

Rassam F, Roos E, van Lienden K, van Hooft J, Klumpen H, van Tienhoven G Langenbecks Arch Surg. 2018; 403(3):289-307.

PMID: 29350267 PMC: 5986829. DOI: 10.1007/s00423-018-1649-2.

References

Zhang M, Li S, Huang G, Lin G, Shuang Z, Lao X . Identification of a novel microRNA signature associated with intrahepatic cholangiocarcinoma (ICC) patient prognosis. BMC Cancer. 2015; 15:64. PMC: 4344737. DOI: 10.1186/s12885-015-1067-6. View

Nakano Y, Tanno S, Koizumi K, Nishikawa T, Nakamura K, Minoguchi M . Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells. Br J Cancer. 2007; 96(3):457-63. PMC: 2360025. DOI: 10.1038/sj.bjc.6603559. View

Sriraksa R, Zeller C, El-Bahrawy M, Dai W, Daduang J, Jearanaikoon P . CpG-island methylation study of liver fluke-related cholangiocarcinoma. Br J Cancer. 2011; 104(8):1313-8. PMC: 3078588. DOI: 10.1038/bjc.2011.102. View

Yang J, Campion M, Liu M, Chaiteerakij R, Giama N, Ahmed Mohammed H . Circulating tumor cells are associated with poor overall survival in patients with cholangiocarcinoma. Hepatology. 2015; 63(1):148-58. PMC: 4684812. DOI: 10.1002/hep.27944. View

Draganov P, Chauhan S, Wagh M, Gupte A, Lin T, Hou W . Diagnostic accuracy of conventional and cholangioscopy-guided sampling of indeterminate biliary lesions at the time of ERCP: a prospective, long-term follow-up study. Gastrointest Endosc. 2012; 75(2):347-53. DOI: 10.1016/j.gie.2011.09.020. View

Clayton R, Clarke D, Currie E, Madhavan K, Parks R, Garden O . Incidence of benign pathology in patients undergoing hepatic resection for suspected malignancy. Surgeon. 2004; 1(1):32-8. DOI: 10.1016/s1479-666x(03)80006-9. View

Chen L, Yan H, Yang W, Hu L, Yu L, Liu Q . The role of microRNA expression pattern in human intrahepatic cholangiocarcinoma. J Hepatol. 2008; 50(2):358-69. DOI: 10.1016/j.jhep.2008.09.015. View

Singhi A, Nikiforova M, Fasanella K, McGrath K, Pai R, Ohori N . Preoperative GNAS and KRAS testing in the diagnosis of pancreatic mucinous cysts. Clin Cancer Res. 2014; 20(16):4381-9. DOI: 10.1158/1078-0432.CCR-14-0513. View

Namwat N, Chusorn P, Loilome W, Techasen A, Puetkasichonpasutha J, Pairojkul C . Expression profiles of oncomir miR-21 and tumor suppressor let-7a in the progression of opisthorchiasis-associated cholangiocarcinoma. Asian Pac J Cancer Prev. 2013; 13 Suppl:65-9. View

10.

de Bono J, Scher H, Montgomery R, Parker C, Miller M, Tissing H . Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res. 2008; 14(19):6302-9. DOI: 10.1158/1078-0432.CCR-08-0872. View

11.

Okamoto K, Miyoshi K, Murawaki Y . miR-29b, miR-205 and miR-221 enhance chemosensitivity to gemcitabine in HuH28 human cholangiocarcinoma cells. PLoS One. 2013; 8(10):e77623. PMC: 3798426. DOI: 10.1371/journal.pone.0077623. View

12.

Xu W, Yang H, Liu Y, Yang Y, Wang P, Kim S . Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. Cancer Cell. 2011; 19(1):17-30. PMC: 3229304. DOI: 10.1016/j.ccr.2010.12.014. View

13.

Yoshikawa D, Ojima H, Kokubu A, Ochiya T, Kasai S, Hirohashi S . Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novel molecular-targeted therapy against cholangiocarcinoma. Br J Cancer. 2009; 100(8):1257-66. PMC: 2676540. DOI: 10.1038/sj.bjc.6604988. View

14.

Rosen C, Heimbach J, Gores G . Liver transplantation for cholangiocarcinoma. Transpl Int. 2010; 23(7):692-7. DOI: 10.1111/j.1432-2277.2010.01108.x. View

15.

Giovannetti E, Del Tacca M, Mey V, Funel N, Nannizzi S, Ricci S . Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. Cancer Res. 2006; 66(7):3928-35. DOI: 10.1158/0008-5472.CAN-05-4203. View

16.

Kim H, Kim M, Lee S, Yoo K, Seo D, Min Y . Tumor vessel: a valuable cholangioscopic clue of malignant biliary stricture. Gastrointest Endosc. 2000; 52(5):635-8. DOI: 10.1067/mge.2000.108969. View

17.

Chusorn P, Namwat N, Loilome W, Techasen A, Pairojkul C, Khuntikeo N . Overexpression of microRNA-21 regulating PDCD4 during tumorigenesis of liver fluke-associated cholangiocarcinoma contributes to tumor growth and metastasis. Tumour Biol. 2013; 34(3):1579-88. DOI: 10.1007/s13277-013-0688-0. View

18.

Plieskatt J, Rinaldi G, Feng Y, Peng J, Yonglitthipagon P, Easley S . Distinct miRNA signatures associate with subtypes of cholangiocarcinoma from infection with the tumourigenic liver fluke Opisthorchis viverrini. J Hepatol. 2014; 61(4):850-8. DOI: 10.1016/j.jhep.2014.05.035. View

19.

Takada M, Masuda N, Matsuura E, Kusunoki Y, Matui K, Nakagawa K . Measurement of cytokeratin 19 fragments as a marker of lung cancer by CYFRA 21-1 enzyme immunoassay. Br J Cancer. 1995; 71(1):160-5. PMC: 2033433. DOI: 10.1038/bjc.1995.33. View

20.

Poplin E, Wasan H, Rolfe L, Raponi M, Ikdahl T, Bondarenko I . Randomized, multicenter, phase II study of CO-101 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma: including a prospective evaluation of the role of hENT1 in gemcitabine or CO-101 sensitivity. J Clin Oncol. 2013; 31(35):4453-61. DOI: 10.1200/JCO.2013.51.0826. View